Biomarkers in Parkinsons Disease


Naperville, IL -- (SBWIRE) -- 07/21/2014 -- Reportstack, provider of premium market research reports announces the addition of Biomarkers in Parkinsons Disease market report to its offering

Biomarkers have been a heavily studied topic of interest, and recently on the rise is the interest in neurodegenerative disorders, particularly Parkinson’s Disease. Although there are many techniques used to track neurodegenerative disease progression, this report will primarily focus on blood-based and cerebrospinal fluid-based biomarkers for this disease. In addition to covering extensive background information, this report will also highlight market growth and outlook, and feature clinical trial and pipeline information.

After the introduction, Chapters 2 and 3 highlight background information relevant to the rest of this report and include definitions and elaborate examples of different types of biomarkers used in the clinic. Chapter 2 concludes with market growth, advantages of biomarkers, disadvantages of biomarkers, and validation techniques. Chapters 3 gives a brief overview of neurodegenerative disorders, also speaking to the market growth and rise in interest in biomarkers over the years.

Chapter 4 gives specifics on Parkinson’s Disease, featuring definitions, symptoms, genetic markers, and current research. As the second leading cause of neurodegeneration in the aging population, researchers are scrambling to find elusive biomarkers that will provide enough information for therapeutic action. Featured in this chapter is an interview with Dr. Andrew West, who speaks about his research and successes with the gene LRRK2. This chapter provides an extensive amount of detail speaking to genetic targets and their use as biomarkers. Furthermore, Chapters 5 and 6 feature Dr. Xuemei Huang (Professor and Vice Chair, Department of Neurology; Professor of Neurosurgery, Radiology, Pharmacology, and Kinesiology Director; Hershey Brain Analysis Research Laboratory for Neurodegenerative Disorders, Penn State University-Milton, S. Hershey Medical Center Department of Neurology) and Dr. Andreas Jeromin, CSO and President of Atlantic Biomarkers. These chapters provide insight to their research utilizing biomarkers as a diagnostic for Parkinson’s Disease.

Chapter 7 includes an elaborate survey analysis exclusively done for this report. Qualifying participants worked with neurobiomarkers, neurodiagnostics, or both. With over 30 survey figures depicting the general R&D group working in this space, this section provides information including: research demographics, targets under investigation, challenges, advantages, and desired features of future diagnostic applications.

Finally, Insight Pharma Reports also garnered a table of clinical and pipeline information related to Parkinson's Disease.

To view the table of contents for this market research report please visit

Roger Campbell
United States
Ph: 888-789-6604